First-Line and Sequential Use of Pazopanib Followed by Mammalian Target of Rapamycin Inhibitor Therapy Among Patients With Advanced Renal Cell Carcinoma in a US Community Oncology Setting

Vogelzang, Nicholas J.; Hackshaw, Michelle D.; Hutson, Thomas E.; Bhowmik, Debajyoti; Yap, Mark; Rembert, Debra; Jonasch, Eric

doi:10.1016/j.clgc.2014.11.001

Cited by 22 publications

(35 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For example, in a retrospective analysis of data from 35 patients treated in the second line with everolimus or temsirolimus following first-line pazopanib, a PFS of 5.7 months and an OS of 16.0 months were reported. [44] In a retrospective analysis, median PFS was significantly prolonged (p = 0.009) in patients treated with anti-VEGF therapy (n = 22, 5.6 months) compared with mTOR inhibitor (n = 13, 2.4 months) following pazopanib therapy in the first (n = 28) or second line (post cytokines; n = 7). [45] Although axitinib was not one of the anti-VEGF therapies used, 20 of the 22 patients were treated with a VEGF-TKI, supporting the use of a second TKI after treatment with pazopanib.…”

Section: Expert Opinionmentioning

confidence: 99%

Pharmacoeconomic and clinical implications of sequential therapy for metastatic renal cell carcinoma patients in Central and Eastern Europe

Vrdoljak

Torday

Szczylik

et al. 2015

Expert Opinion on Pharmacotherapy

View full text Add to dashboard Cite

Introduction:The incidence and mortality rates of kidney cancer in the Central and Eastern European (CEE) region are among the highest in the world. Access to second and subsequent lines of metastatic renal cell carcinoma (mRCC) therapies is highly varied in the region. Despite the increasing body of evidence supporting the clinical benefit of multiple lines of treatment, access to treatment beyond first line is restricted in many of these countries. Areas covered: The adoption of targeted therapies for the first-line treatment of mRCC in the region was slow and faced many obstacles. In order to evaluate the current status of treatment beyond the first-line setting in the CEE region, this review examines the availability and reimbursement of mRCC drugs and clinical practice in institutions that treat patients with mRCC. Expert opinion: This review highlights the need to raise awareness among physicians, payers and regulators on clinical trial and cost-effectiveness data regarding the treatment of mRCC beyond the first line. The obstacles to mRCC drug access highlighted in this review need to be overcome to ensure that patients are receiving the best treatment available.

show abstract

Section: Expert Opinionmentioning

confidence: 99%

Pharmacoeconomic and clinical implications of sequential therapy for metastatic renal cell carcinoma patients in Central and Eastern Europe

Vrdoljak

Torday

Szczylik

et al. 2015

Expert Opinion on Pharmacotherapy

View full text Add to dashboard Cite

show abstract

“…Профиль нежелательных явлений у пациентов, полу-чавших пазопаниб в качестве терапии первой линии при метастатическом ПКР, в рутинной клинической практике в целом соответствует результатам исследова-ний III фазы [19][20][21][22][23][24][25][26]. Так, диарея описывается в 16-52% наблюдений, артериальная гипертензия в 24-49%, тош-нота/рвота в 24-44%, анорексия/потеря массы тела в 7-27% и усталость в 11-58%.…”

Section: профиль безопасности и токсичностиunclassified

“…Так, диарея описывается в 16-52% наблюдений, артериальная гипертензия в 24-49%, тош-нота/рвота в 24-44%, анорексия/потеря массы тела в 7-27% и усталость в 11-58%. Эти реакции наиболее часты и описаны целым рядом исследователей (n = 38-278) [19][20][21][22][23][24]26].…”

Section: профиль безопасности и токсичностиunclassified

“…Аномальные тесты функции печени (например, повы-шение AЛT, AСT или билирубина) имели место у 13-36% пациентов; 3-4-я степень токсичности -у ≤15,7% паци-ентов [19][20][21][25][26]. Частота отмены препарата из-за побочных эффектов в разных исследованиях варьирова-ла от 6 до 15% [19][20][21][22]24].…”

Section: профиль безопасности и токсичностиunclassified

“…Частота отмены препарата из-за побочных эффектов в разных исследованиях варьирова-ла от 6 до 15% [19][20][21][22]24].…”

Section: профиль безопасности и токсичностиunclassified

See 2 more Smart Citations

Pazopanib as first-line therapy for patients with metastatic kidney cancer

Алексеев¹,

Shevchuk²

2018

Med. sov.

View full text Add to dashboard Cite

Б.Я. АЛЕКСЕЕВ, д.м.н., профессор, И.М. ШЕВЧУК, к.м.н. Национальный медицинский исследовательский центр радиологии Минздрава России, Москва ПАЗОПАНИБ -ПРЕПАРАТ ПЕРВОЙ ЛИНИИ ТЕРАПИИ У БОЛЬНЫХ С МЕТАСТАТИЧЕСКИМ РАКОМ ПОЧКИ Пазопаниб (Вотриент®) -пероральный низкомолекулярный мультикиназный ингибитор, который в первую очередь инги-бирует рецептор 1, 2 и 3 сосудистого эндотелиального фактора роста, рецепторы α и β тромбоцитарного фактора роста эндотелия и рецепторы c-kit-фактора стволовых клеток. В предварительных экспериментах с использованием моделей ангиогенеза у мышей и кроликов пазопаниб ингибировал ангиогенез, вызванный комбинированным фактором роста эндо-телия сосудов и основным фактором роста фибробластов. Хотя препарат был разработан как терапевтический мультиопу-холевый агент, в настоящее время во многих странах он одобрен для применения при распространенной саркоме мягких тканей и почечно-клеточном раке (ПКР). В мультицентровых рандомизированных исследованиях по изучению эффектив-ности пазопаниба в качестве препарата первой линии у больных с метастатическим ПКР он продемонстрировал значитель-но лучшую безрецидивную выживаемость (БРВ) по сравнению с цитокиновой терапией и одинаковое время до прогресси-рования в случае применения сунитиниба. Кроме того, побочные эффекты, такие как нарушение функции печени и артери-альная гипертензия, как правило, управляемы, и с точки зрения качества жизни и экономической эффективности пазопаниб представляется более предпочтительным агентом по сравнению с другими альтернативными препаратами. Ключевые слова: метастатический почечно-клеточный рак, мультитаргетные ингибиторы тирозинкиназ, пазопаниб. B.Ya. ALEKSEEV, I.M. SHEVCHUK National Medical Research Radiological Center of the Ministry of Health of Russia, Moscow PAZOPANIB AS FIRST-LINE THERAPY FOR PATIENTS WITH METASTATIC KIDNEY CANCER Pazopanib (Votrient®) is an oral small-molecule multi-kinase inhibitor that predominantly inhibits vascular endothelial growthfactor receptor-1, -2 and -3, platelet-derived growth factor receptor-α and -β and the stem cell factor receptor c-Kit. In preliminary experiments using mouse and rabbit models of angiogenesis, pazopanib inhibited angiogenesis caused by a combined vascular endothelial growth factor and a major fibroblast growth factor. Although the drug was developed as a therapeutic multi-tumour agent, it is currently approved in many countries for the treatment of advanced soft tissue sarcoma and renal cell carcinoma (RCC). In multicentre, randomized trials of the efficacy of pazopanib as a first-line therapy in patients with metastatic RCC, progression-free survival (PFS) was significantly greater in pazopanib recipients than in cytokine recipients and pazopanib was noninferior to sunitinib with respect to time to disease progression. In addition, side effects such as liver dysfunction and hypertension can be usually managed, and pazopanib is likely to be a more preferred cost-effective option and shows better quality-of-life compared to other alternative drugs.

show abstract

Pazopanib: a Review in Advanced Renal Cell Carcinoma

Frampton

2017

Targ Oncol

View full text Add to dashboard Cite

Pazopanib (Votrient®), an orally administered multi-targeted tyrosine kinase inhibitor that predominantly inhibits vascular endothelial growth factor receptor-1, -2 and -3, platelet-derived growth factor receptor-α and -β, and the stem cell factor receptor c-Kit, is approved in the EU, the USA and other countries for the treatment of advanced renal cell carcinoma (RCC). In randomized controlled trials in patients with advanced, predominantly clear-cell RCC, pazopanib significantly improved progression-free survival (PFS) compared with placebo in both treatment-naïve and cytokine-pretreated patients and, as a first-line therapy, was noninferior to intermittent sunitinib with respect to PFS. However, pazopanib had a tolerability profile that was distinguishable from that of sunitinib, based on lower incidences of most adverse events, particularly those associated with discomfort, such as fatigue, hand-foot syndrome and stomatitis. Consistent with this, health-related quality of life (HR-QOL) measures evaluating fatigue, hand/foot soreness and mouth/throat soreness significantly favoured pazopanib over sunitinib. In addition, significantly more patients expressed a preference for pazopanib over sunitinib, primarily because of better overall HR-QOL and less fatigue. Efficacy and tolerability findings from these prospective clinical trials have been substantiated by evidence from a number of retrospective studies evaluating unselected real-world patients with metastatic RCC who received pazopanib (or sunitinib) as a first-line therapy. Thus, data from clinical trials supplemented with that from clinical practice support the use of pazopanib as a standard or alternative first-line treatment for advanced or metastatic RCC.

show abstract

First-Line and Sequential Use of Pazopanib Followed by Mammalian Target of Rapamycin Inhibitor Therapy Among Patients With Advanced Renal Cell Carcinoma in a US Community Oncology Setting

Cited by 22 publications

References 16 publications

Pharmacoeconomic and clinical implications of sequential therapy for metastatic renal cell carcinoma patients in Central and Eastern Europe

Pharmacoeconomic and clinical implications of sequential therapy for metastatic renal cell carcinoma patients in Central and Eastern Europe

Pazopanib as first-line therapy for patients with metastatic kidney cancer

Pazopanib: a Review in Advanced Renal Cell Carcinoma

Contact Info

Product

Resources

About